• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Healthcare

Swedish GPs cash in on pharmaceutical reform

pharmacy-pills
  • Karin Wasteson
  • 02 May 2013
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Since the Swedish pharmaceutical sector was reformed four years ago, private equity firms have piled into the industry. Today, those investments are demonstrating impressive returns.

For almost 40 years, Sweden was one of the few countries in the world where private retail of pharmaceuticals was banned. Privatised by the centre-right party in late 2009, a majority of the government-owned pharmacies were rebranded in 2010 as they were transferred to new owners.

This gave private equity firms the opportunity to take over the newly privatised pharmacies. At the time of completing the pharmacy sell-off, three of the major chains were owned by private equity firms: Apoteket Hjärtat by Altor, Medstop Holding AB by Segulah and Vårdapoteket i Norden AB by Investor and Priveq.

Stockholm-based firm Segulah secured the purchase of 62 of the formerly state-owned pharmacies through Medstop Group Holding AB. At the beginning of April, Segulah sold Medstop to Oriola-KD, a Finnish pharmaceutical retail and wholesale company that operates in Finland, Sweden and Russia.

The transaction, which is expected to be completed in the second quarter of 2013, values the company at SEK 1.46bn including a conditional earn-out payment. Following the acquisition, Oriola-KD will have around 300 pharmacies in Sweden and its share of the Swedish pharmacy retail market will increase from 14% to approximately 21%.

In 2009, Oriola-KD Corporation, via its company Kronans Droghandel Retail AB - together with joint owner Kooperativa Förbundet (KF) - acquired 100% of the shares in the second cluster of pharmacies at the time of deregulation, officially known as Pharmacy Company Sweden 2 AB.

Healthy investment
Another healthcare exit took place in mid-April this year. Following the de-regulation, or re-regulation of the Swedish pharmacy market, Vårdapoteket i Norden bought 24 pharmacies located near hospitals. Its private equity owners Investor Growth Capital and Priveq Investment agreed to sell their holdings in pharmacies operator Vårdapoteket to Apotek Hjärtat on 16 April.

Based in Malmö, Vårdapoteket was the first player that broke the de facto monopoly that Apoteket AB held in the pharmaceutical market. Since its inception in 2010, the chain has grown from the original 24 outpatient pharmacies to its current 27 pharmacies. Apotek Hjärtat, owned by Altor Equity Partners, is today the largest independent pharmacy chain after Apoteket AB, with slightly more than 270 pharmacies and around 2,000 employees.

Since the monopoly of state-owned Apoteket AB ended, the number of pharmacies in Sweden has increased by around 345.

Despite the two major exits in the healthcare sector, the Nordic private equity market's first quarter in 2013 saw lower activity than the same period last year overall.

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Healthcare
  • Regulation
  • Nordics
  • Segulah
  • Priveq Partners
  • Sweden

More on Healthcare

Clinical trials and biotechnology
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • Buyouts
  • 04 September 2023
Jan Cerny of BHM Group
BHM Group builds on PE strategy, eyes European medtech and renewable energy acquisitions

Czech Republic-headquartered family office is targeting DACH and CEE region deals

  • Investments
  • 01 September 2023
Big Ben and British flag London UK
CMA scrutiny of high-leverage PE divestment purchases expected to increase

PE could stand to lose its historic advantage with heightened regulatory baggage

  • Regulation
  • 21 August 2023
Deals and business agreements
Evoco expects portfolio acquisitions, assesses potential exits in 2H23

Switzerland-headquartered GP is currently deploying equity via its EUR 162m Evoco TSE III fund

  • Investments
  • 21 August 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013